Chinese Integrated Guideline on Clinical Management of Gastric Precancerous Conditions and Lesions / 胃肠病学

Standardized diagnosis and effective treatment of gastric precancerous conditions and lesions are of great importance in preventing gastric cancer. This guideline was developed by five associations of traditional Chinese medicine and Western medicine based on the current status of prevalence, clinical diagnosis and treatment, integrating the Western medicine and traditional Chinese medicine with multidisciplinary participation, to provide targeted suggestions about essentials and strategies from the definition, epidemiology, diagnosis, staging, surveillance, treatment and evaluation of gastric precancerous conditions and lesions. It may play a guidance role in standardized diagnosis and treatment of gastric precancerous conditions and lesions and achieving effective secondary prevention of gastric cancer.

Minimally invasive integrated traditional Chinese and Western medicine therapy for hepatolithiasis based on the SELECT concept / 临床肝胆病杂志

Hepatolithiasis is difficult to treat in clinical practice and has high recurrence rate and incidence rate of complications, improper diagnosis and treatment can easily lead to hepatic insufficiency, and thus it has become one of the difficult problems to be solved in clinical practice. With the improvement of medical equipment and the wide application of various minimally invasive endoscopic techniques, most patients with hepatolithiasis can receive effective treatment. Traditional Chinese medicine therapy can prevent the recurrence of calculi and promote patients’ recovery during the perioperative period. Based on the SELECT (Spyglass, ERCP, Laparoscopy, EUS, Choledochoscopy, Traditional Chinese Medicine) concept, minimally invasive treatment with a combination of various endoscopies should be selected according to the type and clinical features of hepatolithiasis and integrated traditional Chinese and Western medicine therapy should be given in the perioperative period to realize the minimally invasive, diversified, and individualized integrated traditional Chinese and Western medicine therapy for hepatolithiasis.

Clinical effect of Jinlong capsules combined with Western medicine treatment in treatment of primary liver cancer: A Meta-analysis / 临床肝胆病杂志

@#ObjectiveTo investigate the clinical effect and adverse events of Jinlong capsules combined with Western medicine treatment in the treatment of advanced primary liver cancer. MethodsPubMed, The Cochrane library, CNKI, Wanfang Data, CBM, and VIP were searched for randomized controlled trials (RCTs) on Jinlong capsules combined with Western medicine treatment in the treatment of advanced primary liver cancer published up to May 2019. The patients treated with Jinlong capsules combined with Western medicine treatment were enrolled as intervention group, and those treated with Western medicine treatment alone were enrolled as control group. Data extraction and quality assessment were performed, and RevMan 5.3 was used to perform the Meta-analysis with a fixed or random effects model. ResultsA total of 26 RCTs were included, with a total of 2318 patients (1175 patients in the intervention group and 1143 patients in the control group). The results of the Meta-analysis showed that compared with Western medicine treatment alone, Jinlong capsules combined with Western medicine treatment had significant increases in response rate (relative risk ［RR］=1.36, 95% confidence interval ［CI］: 125-1.49, P＜0.001), 1-year survival rate (RR=1.29, 95%CI: 1.14-1.47, P＜0.001), Karnofsky Performance Scale score (RR=137, 95%CI: 1.19-1.59, P＜0.001), peripheral blood CD3+ T lymphocytes (mean difference ［MD］=11.18, 95%CI: 268-1968, P=0.01), CD4+ T lymphocytes (MD=6.43, 95%CI: 3.82-9.05, P＜0.001), and CD4+/CD8+ ratio (MD=0.31, 95%CI: 026-0.36, P＜0.001), as well as significant reductions in rate of progression (RR=0.41, 95%CI: 0.29-0.57, P＜0001), rate of leucopenia (RR=0.65, 95%CI: 0.57-0.75, P＜0.001), incidence rate of gastrointestinal reactions (RR=0.72, 95%CI: 059-088, P=0.001), and peripheral blood CD8+ T lymphocytes (MD=-4.68, 95% CI: -5.84 to -3.51, P＜0001). ConclusionJinlong capsules combined with Western medicine treatment has a marked clinical effect in the treatment of advanced primary liver cancer with few adverse events and thus holds promise for clinical application.

Clinical efficacies of Jiangzhi Decoction for lipid metabolism disorder patients with traditional Chinese medicine syndrome of phlegm and turbidity retardation / 中华全科医师杂志

A total of 101 lipid metabolism disorder patients with traditional Chinese medicine (TCM) syndrome of phlegm and turbidity retardation were collected and randomly divided into group A:Jiangzhi Decoction (JZF) alone (n =30),group B:atorvastatin (ATV) alone (n =39) and group C:JZF plus ATV (n =32).Lipid level,liver and kidney function,total effective rate and TCM scores were observed after a course of 2 weeks.Total effective rate:Group C was significantly superior to group B (90.62％ vs.76.92％,u =1.97,P ＜ 0.05) ; TCM score:Group C had a statistically superior advantage over groups A andB (C vs.A,90.62％ vs.80.00％,u=1.98,P＜0.05; Cvs.B,90.62％ vs.51.28％,u=4.11,P ＜0.01); TC and Improvements of total cholesterol (TC) and low-density lipoprotein-cholesterol (LDL-C):Group C demonstrated marked decreases in both TC and LDL (CTC & CLDL-C vs.group A,P ＜ 0.01 ; CTC & CLDL-C vs.group B,P ＜ 0.01),no abnormal liver or kidney function occurred during the follow-up period.Thus JZF and ATV may have synergic lipid-lowering effects.And single uses of JZF and ATV have no marked differences in short term efficacy.